Ovarian cancer
Conditions
Interventions
Experimental group:The patients were treated with platinum drugs and cytotoxic drugs pemetrexed combined with anlotinib
Sponsors
The First Hospital Affiliated to Army Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Females aged 18-70 years with platinum-resistant (defined as PFI =3.0*10^9/L, neutrophil count>=1.5*10^9/L, platelet count>=100*10^9/L, hemoglobin concentration>=90g/L. 9. Liver function: AST and ALT=60ml/min.
Exclusion criteria
Exclusion criteria: 1.The presence of symptoms and signs of active central nervous system metastasis. 2.Patients with >=4 recurrences. 3.Patients with allergy to platinum-based chemotherapy agents. 4.Allergy to pemetrexed, anlotinib and their excipients. 5.Accompanied by diseases that endanger the safety of the subjects or affect the completion of the study, including poorly controlled hypertension, poorly controlled diabetes, chronic obstructive pulmonary disease, pulmonary embolism, cerebral thrombosis or cerebral hemorrhage within half a year, myocardial infarction, severe congestive heart failure, etc. 6.Patients judged by the investigator to be ineligible for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CR or PR; | — |
Secondary
| Measure | Time frame |
|---|---|
| Kelim score;Disease control rate;Duration of response;Progression-free survival; | — |
Countries
China
Contacts
Public ContactLi Deng
The First Hospital Affiliated to Army Medical University
Outcome results
None listed